Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatmentPhilip H Keiser
University of Texas Southwestern Medical Center, Dallas, Texas, USA
BMC Infect Dis 5:2. 2005
..Hyperlipidemia secondary to protease inhibitors (PI) may abate by switching to anti-HIV medications without lipid effects...
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adultsEdwin DeJesus
IDC Research, Altamonte Springs, FL 32701, USA
Clin Infect Dis 39:1038-46. 2004
..Evaluating other unique nucleoside reverse-transcriptase inhibitor (NRTI) combinations for long-term viral suppression is desirable...
- Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects
Edwin DeJesus
Infectious Disease Consultants, Altamonte Springs, Florida 32701, USA
J Infect Dis 188:1009-16. 2003
..There were no episodes of thrombotic microangiopathy. Valacyclovir was safe and effective for the suppression of recurrent genital herpes infection in HIV-infected individuals...
- Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial
Edwin DeJesus
IDC Research Initiative, Altamonte Springs, FL, USA
Clin Infect Dis 39:411-8. 2004
..Median increase above baseline in CD4(+) cell count was similar (q.d. group, +144 cells/mm(3); b.i.d. group, +146 cells/mm(3)), and the incidences of adverse events, disease progression, and HIV-associated conditions were comparable...
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-Edwin DeJesus
Orlando Immunology Center, Orlando, FL, USA
Lancet 379:2429-38. 2012
..We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection...
- Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults
Edwin DeJesus
Orlando Immunology Center, Orlando, FL, USA
Antivir Ther 15:711-20. 2010
..A pharmacokinetic trial was conducted to evaluate the potential for once-daily etravirine in antiretroviral regimens without and with darunavir/ritonavir...
- Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
Roberto Ortiz
Orlando Immunology Center, Orlando, Florida, USA
AIDS 22:1389-97. 2008
....
- Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study
Richard Elion
George Washington University, Washington, DC, USA
HIV Clin Trials 7:324-33. 2006
....
- Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
Edwin DeJesus
Orlando Immunology Center, Orlando, FL, USA
J Acquir Immune Defic Syndr 43:1-5. 2006
..CONCLUSIONS: GS-9137 demonstrated substantial short-term antiviral activity and was well tolerated as monotherapy, thus warranting further study...
- Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis
Anton L Pozniak
Chelsea and Westminster Hospital, London, United Kingdom
J Acquir Immune Defic Syndr 43:535-40. 2006
..7 vs. 5.5 kg; P < 0.001). CONCLUSION: Over 96 weeks, the combination of TDF, FTC, and EFV was superior to fixed-dose ZDV/3TC + EFV for achieving and maintaining an HIV RNA level <400 copies/mL and an increase in CD4 cells...
- Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects
Edwin DeJesus
Orlando Immunology Center, Florida, USA
Antimicrob Agents Chemother 50:3157-9. 2006
..A regimen of 700 mg of FPV BID plus 100 mg of RTV BID may be coadministered with NVP without dose adjustment...
- Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis
Jose R Arribas
Internal Medicine Service, Hospital de La Paz, Madrid, Spain
J Acquir Immune Defic Syndr 47:74-8. 2008
..As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important...
- Advances in HIV therapeutics: news from the 4th International AIDS Society Conference
Brian A Boyle
AIDS Read 17:484-90. 2007
- Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection
Peter Ruane
Private Practice, Los Angeles, California, USA
HIV Clin Trials 7:229-36. 2006
....
- Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients
Jacob Lalezari
Quest Clinical Research, San Francisco, CA 94115, USA
J Infect Dis 197:721-7. 2008
..HGS004 is a fully human immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5) with robust in vitro activity against a diverse panel of CCR5-tropic human immunodeficiency virus type 1 (HIV-1) isolates...
- Adherence to enfuvirtide and its impact on treatment efficacy
Jurgen Rockstroh
Medizinische Klinik I, University of Bonn, Bonn, Germany
AIDS Res Hum Retroviruses 24:141-8. 2008
..825). Adherence was high in patients receiving the self-injectable ARV enfuvirtide. In addition, the inclusion of ENF did not negatively impact adherence to the ARV regimen as a whole...
- Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine
Edwin DeJesus
Orlando Immunology Center, Orlando, Florida 32803, USA
HIV Clin Trials 9:103-14. 2008
....
- Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study
Richard Elion
George Washington University, Washington, DC, USA
HIV Clin Trials 9:152-63. 2008
....
- Update on antiretroviral therapy: the 15th CROI
Brian A Boyle
Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, USA
AIDS Read 18:273-8, C3. 2008
- Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus
Gregory J Dore
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
J Infect Dis 189:1185-92. 2004
..Lamivudine has potent activity against both HIV-1 and HBV; however, lamivudine-resistance mutations in HBV frequently develop...
- Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M Gulick
Weill Cornell Medical College, New York, NY 10065, USA
N Engl J Med 359:1429-41. 2008
..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
- Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
Gerd Fatkenheuer
Universitätsklinik Köln, Cologne, Germany
N Engl J Med 359:1442-55. 2008
....
- The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
Joseph Eron
Department of Medicine, Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
Lancet 368:476-82. 2006
..INTERPRETATION: Fosamprenavir-ritonavir twice daily in treatment-naive patients provides similar antiviral efficacy, safety, tolerability, and emergence of resistance as lopinavir-ritonavir, each in combination with abacavir-lamivudine...
- Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study
Joseph C Gathe
Therapeutic Concepts, P.A, Houston, Texas, USA
Clin Ther 28:745-54. 2006
..Adverse events had generally developed by 48 weeks of therapy and did not occur at a higher frequency through 120 weeks of treatment...
- Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations
Mike Youle
Royal Free Hospital Centre for HIV Medicine, Royal Free Hospital, London, UK
HIV Clin Trials 7:86-96. 2006
..g., ENF) for triple-class-experienced patients...
- A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
Jacob P Lalezari
Quest Clinical Research, San Francisco, CA 94115, USA
AIDS 17:691-8. 2003
..Secondary objectives included the determination of enfuvirtide pharmacokinetics and antiviral activity and the immunological response to the enfuvirtide-containing regimen...
- A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults
Jacob P Lalezari
Quest Clinical Research and Mount Zion Hospital UCSF, San Francisco, Calif, USA
Antivir Ther 8:279-87. 2003
..8% of patients in the control group. These results indicate that enfuvirtide has a favourable safety profile and is a promising new antiviral agent for HIV-infected patients who have been on previously failing ARV regimens...
- Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1
Daniel R Kuritzkes
Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA
J Infect Dis 189:286-91. 2004
..We wished to determine the safety and anti-human immunodeficiency virus (HIV) type 1 activity of single doses of TNX-355, a humanized IgG4 anti-CD4 monoclonal antibody with potent activity against HIV-1 in vitro, in HIV-infected subjects...
- Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus
Peter J Ruane
Tower Infectious Diseases Medical Associates, Inc, Los Angeles, California 90049, USA
Pharmacotherapy 24:307-12. 2004
..To compare the virologic activity of zidovudine monotherapy administered as 600 mg once/day versus 300 mg twice/day...
- SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients
Joseph C Gathe
Therapeutic Concepts, P.A, Houston, Texas, USA
AIDS 18:1529-37. 2004
..CONCLUSION: As a first choice protease inhibitor with a low daily pill burden, FPV/r QD was well tolerated and provided potent, durable antiviral suppression...
- Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
Joel E Gallant
Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
JAMA 292:191-201. 2004
..Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor...
- New nucleoside/nucleotide backbone options: a review of recent studies
Peter J Ruane
J Acquir Immune Defic Syndr 37:S21-9. 2004
....
- Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
Margaret Johnson
AIDS 19:153-62. 2005
- Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study
Graeme J Moyle
Chelsea and Westminster Hospital, HIV Clinic, London, United Kingdom
J Acquir Immune Defic Syndr 38:417-25. 2005
..7%). ABC administered once daily in combination with 3TC and EFV administered once daily was non-inferior to the ABC twice-daily dosing schedule when combined with 3TC and EFV over 48 weeks...
- 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
Margaret Johnson
Royal Free Hospital, London, UK
AIDS 20:711-8. 2006
..Results of extended follow-up to 96 weeks are presented...
- Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
Joel E Gallant
Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
N Engl J Med 354:251-60. 2006
..Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere...
- Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients
Michael G Sension
Comprehensive Care Center, Fort Lauderdale, Florida 33311, USA
HIV Clin Trials 3:361-70. 2002
....
- Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL)
Nestor Sosa
Social Security Hospital, Panama City, Panama
J Acquir Immune Defic Syndr 40:422-7. 2005
..A dual-nucleoside backbone of ABC and 3TC administered once or twice daily is effective, durable, and well tolerated...
- Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial
Mark S Sulkowski
J Acquir Immune Defic Syndr 39:504-6. 2005
- Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients
Martin Markowitz
The Aaron Diamond AIDS Research Center, New York, NY 10016, USA
J Acquir Immune Defic Syndr 39:257-64. 2005
..The ESS40013 study tested 4-drug induction followed by 3-drug maintenance as initial antiretroviral therapy (ART) to reduce HIV RNA rapidly and then to simplify to an effective yet more convenient and tolerable regimen...
- Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
Margaret Johnson
Royal Free Hospital, London, UK
AIDS 19:685-94. 2005
....
- Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects
Melanie Thompson
AIDS Research Consortium of Atlanta, Atlanta, Georgia 30308, USA
AIDS 20:397-404. 2006
..To investigate the pharmacokinetics, safety/tolerability and antiviral activity of enfuvirtide administered once-daily (QD) versus twice-daily (BID)...
- First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America
Benjamin Young
Division of General Internal Medicine, University of Colorado, Rose Medical Center, Denver, Colorado 80220, USA
AIDS 22:1673-5. 2008
....
